| Course | HCR 579 Translational Research in Drug Discovery and Development |
|---|---|
| Module | Module 5 |
| Paper type | Annotated bibliography |
| Length | About 508 words, 4 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 579 Module 5
Annotated Bibliography: Patient-Derived Organoids as a Translational Approach in Cancer
Student Name
MS in Regulatory Science, Arizona State University
HCR 579: Translational Research in Drug Discovery and Development
Instructor Name
Month Day, Year
Annotated Bibliography: Patient-Derived Organoids as a Translational Approach in Cancer
Introduction
Animal models and flat cell cultures often fail to predict how human cancers respond to drugs, and that gap contributes to the high failure rate of cancer drugs in clinical trials. Patient-derived organoids are proposed as a bridge: grown from a patient's tumor, they keep much of its structure and genetic makeup. This bibliography gathers sources on whether that promise holds.
Annotations
1. Organoids in Cancer Research
Summary: This review describes how organoids are grown from normal and tumor tissue, how they preserve features of the original tissue and how they are used for studying cancer biology, testing drugs and modeling individual patients (Drost & Clevers, 2018). Evaluation: Written by leaders in the field, it is authoritative but also enthusiastic, and it predates several of the clinical prediction studies. Translational meaning: It explains the biological basis for using organoids as a step between the laboratory and the patient.
2. Organoids and Gastrointestinal Cancers
Summary: Researchers built a living biobank of organoids from heavily pretreated patients with metastatic colorectal and gastroesophageal cancer enrolled in early trials, showed that organoids resembled the original tumors and compared drug responses in organoids with patients' actual responses, finding that organoids could recapitulate clinical responses (Vlachogiannis et al., 2018). Evaluation: A landmark study, but small and drawn from a specialized trial population. Translational meaning: It moved organoids from a research model toward a possible clinical test.
3. Predicting Chemotherapy Response in Colorectal Cancer
Summary: In a prospective study, organoids grown from metastatic colorectal lesions predicted response to irinotecan-based therapy in more than 80% of patients without misclassifying those who would benefit, but failed to predict response to 5-fluorouracil plus oxaliplatin (Ooft et al., 2019). Evaluation: Prospective design is a strength; the mixed results are an honest limit. Translational meaning: Organoid prediction may work for some drugs and not others, so validation must be drug-specific.
4. Pancreatic Cancer Organoid Profiling
Summary: A library of pancreatic cancer organoids reflected the mutations and subtypes of the disease, showed varied responses to chemotherapy and yielded gene expression signatures of chemosensitivity that predicted responses for many patients (Tiriac et al., 2018). Evaluation: Large and molecularly detailed, though clinical comparisons were partly case-based. Translational meaning: It suggests organoids can generate biomarkers, not only drug tests.
5. The FDA Modernization Act 2.0
Summary: The 2022 law amended the federal drug statute so that nonclinical tests supporting a drug application may include cell-based assays, organ chips and computer models instead of animal studies (Consolidated Appropriations Act, 2023, § 3209). Evaluation: The law permits rather than requires alternatives, and acceptance depends on validation. Translational meaning: It creates a regulatory path for organoid data in drug development.
Synthesis
The sources agree that organoids preserve key features of patients' tumors and can, in some settings, predict treatment response. They also show that prediction varies by drug and cancer type and that most studies are small. The 2022 law gives regulators room to accept such data, but broad use will depend on larger prospective studies.
References
Consolidated Appropriations Act, 2023, Pub. L. No. 117-328, § 3209, 136 Stat. 4459 (2022).
Drost, J., & Clevers, H. (2018). Organoids in cancer research. Nature Reviews Cancer, 18(7), 407-418. https://doi.org/10.1038/s41568-018-0007-6
Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., Prevoo, W., Snaebjornsson, P., van der Velden, D., Klein, M., Chalabi, M., Boot, H., van Leerdam, M., Bloemendal, H. J., Beerepoot, L. V., . . . Voest, E. E. (2019). Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Science Translational Medicine, 11(513), eaay2574. https://doi.org/10.1126/scitranslmed.aay2574
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., Miyabayashi, K., Young, C. M., Patel, H., Ma, M., LaComb, J. F., Palmaira, R. L. D., Javed, A. A., Huynh, J. C., Johnson, M., . . . Tuveson, D. A. (2018). Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discovery, 8(9), 1112-1129. https://doi.org/10.1158/2159-8290.CD-18-0349
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., . . . Valeri, N. (2018). Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 359(6378), 920-926. https://doi.org/10.1126/science.aao2774
HCR 579 Module 5 instructions, in plain terms
At 125 points, HCR 579's Annotated Bibliography outweighs every other written item, and it falls in Module 5 on translational approaches. The syllabus lists it among the course's papers, with instructions and rubric in Canvas. Choose a translational approach, a method or model that helps carry discoveries from the laboratory to patients, such as organoids, organ-on-a-chip systems, humanized mouse models, biomarker-driven trial designs or computational modeling, and gather sources that show both its promise and its limits. A good set mixes a review for background, primary studies that test the approach and, where possible, a regulatory source showing how the approach can be used in drug development. Each annotation should summarize, appraise and explain translational meaning, and a short synthesis at the end shows you see how the sources fit together.
How the HCR 579 Module 5 example is put together
A short introduction explains the problem the approach addresses and what organoids are. Five annotations follow under descriptive headings, each with three labeled parts: summary, evaluation and translational meaning, with in-text citations and key results. The sources are ordered from background to evidence to regulation: a review, three prediction studies in different cancers and the 2022 law. A margin note explains why the law is included. The synthesis states where the sources agree and what larger studies still need to show, and full references appear in APA format. Sources are ordered from background to evidence to regulation, so the reader moves from what organoids are to whether they work to how they can be used.
HCR 579 Module 5 rubric: what earns full marks
For 125 points, graders look for a bibliography that chooses a focused translational approach, uses credible and varied sources, summarizes each accurately with key findings, appraises strength and limits honestly, explains each source's relevance to translation and closes with a synthesis, all in correct APA style. Old or non-peer-reviewed sources, annotations without appraisal, topics without edges and inflated findings all cost marks, such as calling an approach validated after small studies. Readers value including a regulatory source, since translational research in this program is studied alongside the rules that govern it.
HCR 579 Module 5 help: mistakes that cost marks
Pick an approach narrow enough for five to eight sources. Include one review for background and several primary studies that test the approach. Add a regulatory or policy source if one exists. Give every annotation the same three parts. Report key numbers and note sample sizes. Write a synthesis that names the main gap in the evidence. If your approach has few clinical studies, the desk can help you find them or choose another. Watch long author lists and consortium authors when formatting references. Keep each annotation to a similar length. Make sure your synthesis states one clear conclusion about the approach's readiness.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 579 and MS in Regulatory Science sample papers
- HCR 579 Module 2: Written Assignment 1: Evaluating a Translational Study
- HCR 579 Module 3: Written Assignment 2: Analysis of an IACUC Application
- HCR 579 Module 4: Written Assignment 3: Dissecting a Phase 0 Study
- HCR 579 Module 6: Assignment 4: Presenting a Precision Medicine Protocol
- HCR 579 Module 7: Ethical Paper: Precision Medicine
- HCR 555 Module 1: Assignment 1: Drug Development From Bench to Market
- HCR 576 Module 1: Paper: Product Profile for a Drug Under Development
- HCR 543 Module 7: Summative Evaluation Paper: Emerging Food Safety Issues
- HCR 563 Module 5: Assignment 3: Annotated Bibliography on Decentralized Trials
HCR 579 Module 5 questions, answered
Where can I find a free HCR 579 Module 5 sample paper?
The full annotated bibliography on patient-derived organoids as a translational approach is on this page.
What are patient-derived organoids?
Small three-dimensional cultures grown from a patient's own tumor that keep much of its structure and genetics.
Can organoids predict how patients respond to cancer drugs?
In some studies and for some drugs, yes; a colorectal study predicted irinotecan response but not response to 5-fluorouracil plus oxaliplatin.
What did the FDA Modernization Act 2.0 change?
It allowed nonanimal methods such as cell-based assays and computer models to support drug applications.
How many points is the HCR 579 annotated bibliography worth?
125 points, the largest single written item in the course.